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Intmducion
A large number ofpublic policies aim
to reduce health risks from exposure to
toxic substances in air, water, and food.
For example, both the Environmental
Protection Agency and the Occupational
Safety and Health Administration have re-
cently promulgated regulations to reduce
human exposure to asbestos. Similarly,
the Food and Drug Administration seeks
more efficientways to ensure that our food
supply remains free from potentially
harmful pesticide residues, other toxic
chemicals, and microorganisms. In esti-
mating the benefits of health and safety
regulations, most researchers have fo-
cused on the value of avoided deaths.1
Only a few studies have estimated the
value of avoiding nonfatal injuries and
some illnesses.23 Nonetheless, avoided
morbidity may be an equally or more im-
portant outcome of health and safety reg-
ulations. For example, reducing the inci-
dence of salmonellosis from contaminated
food will not save many lives, but it will
save many thousands ofrestricted activity
days that would have resulted from mild
cases of the disease.
We present a quality-adjusted life-
year method for valuing the changes in
health status associated with asthma, a
headache, a cough, bronchitis, and arthri-
tis. Our model determines changes in
health attributes for different illnesses and
then estimates the value of the corre-
sponding welfare losses using secondaiy
data. We compare our estimates with
those using estimation techniques that re-
quire primary data collection.
ate) in terms of patient symptoms, mor-
tality rates, durations of treatment and
recovery, frequently used medical treat-
ment, and functional status during treat-
ment and recovery. We define functional
status during the illness as one of four
states: in the hospital, at home in bed, at
home but not in bed, and at work but with
some functional impairment. The infor-
mation needed for these descriptions is
usually available in the clinical literature
but may require some discretionary judg-
ments when data are missing.
The third step is to determine the time
spent in different health states with and
without the illness.4 For simplicity, we as-
sume that in the absence of an illness, a
person is in perfect health over the same
time period. (Although we assume that,
absent a specific illness, an individual is in
perfect health, the model can accommo-
date relaxing this assumption if the data
are available. Using age-specific disability
days to measure health status, Lipscomb5
found that the deviation from perfect
health was no higher than 6%.) We use
current national life tables to estimate the
average remaining life expectancy at a
given age. Our model can use any set of
health states that have relative utility
weights and is general enough to be ap-
plied to all illnesses. We use the Bush et
al.6 health status index for acute effects
because its utility weights were derived
assuming a 1-day duration for each health
state. We use the Rosser and Kind7 health
status index for chronic effects because a
lifetime in each health state was assumed
for deriving utility weights.
Conceptual Framework
Our quality-adjusted life-year
method formorbidityvaluation consists of
six steps. The first step is to identify the
illness(es) avoided. To facilitate later steps
of the model, we subdivide the illnesses
into three categories: acute illnesses,
chronic illnesses, and cancers.
In the second step, we characterize
the health impact for each illness (subdi-
vided by level of severity where appropri-
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In the fourth step, we estimate the
expected quality-adjusted life-years or
life-days lost for each illnessbycombining
the information on time spent in different
health states with and without the illness
with the relative utility weights for those
health states. Figure 1 illustrates the con-
cept for chronic and acute illnesses.8
In the fifth step, we estimate willing-
nesstopayto avoid losing aquality-adjusted
life-year using the method proposed by
Moore and Viscusi.9 We choose from the
literature a representative estimate for the
value ofa statistical life, which serves as the
estimate of willgness to pay to avoid the
index state of death from a previous condi-
tionofperfect health. (In principle,we could
use the value of avoiding a nonfatal health
effect as our index state. However, morbid-
ityvaluation estimates inthe literature rarely
descnibe the clinical characteristics of the
condition adequately enough to use our
quality-of-life method.) Next, we compute
thevalue ofa quality-adjusted life-yearfrom
the estimated value of a statistical life using
two steps. First, we convert remaining life-
time to total discounted life-years using the
following calculation:
(1) Total Discounted Life-Years
Remaining =
T 1
(1 + -n Pr(AMi4n),
i =n_(1+ry
where T is the maximum life span, r is the
discount rate, n is the current age, and
Pr(AiL4n) is probability alive at age i given
alive at age n.
We then compute the value of a qual-
ity-adjusted life-year as follows:
(2) $Quality-Adjusted Life-Year
(r%o discount) =
Value of a Statistical Life
Total Discounted Life-Years Remaining.
Using these equations and a $5 mil-
lion value of a statistical life at age 40, we
calculated the value of a quality-adjusted
life-year as $139 000 at a 0% discount rate
and $226 244 at a 3% discount rate. Our
choice of $5 million as the value of a sta-
tistical life was motivated by at least two
factors. First, this estimate is reported in a
well-designed and often-quoted study by
Moore and Viscusi.9-10 Second, $5 million
is the midpoint of a range of estimates
from studies reviewed by Fisher et al.'.
In the sixth and final step, we esti-
mate the value of avoiding each illness by
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multipying the quality-adjusted life-years
lost by the dollarvalue of a quality-adjusted
life-year.
Estimation Results
Table 1 presents our estimates of the
quality-adjusted life-days lost for a daywith
asthma, a headache, or a cough or a year
with chronic bronchitis or arthritis. We use
these estimates of the quality-adjusted life-
days lost to then derive estimates of the
dollar value of avoiding these illnesses.
(Mauskopf et al.8 and Mauskopf and
French"1 report more extensive informa-
tionon illness characteristics, health states,
utility losses, and morbidity valuations for
various foodbome illnesses.) Table 2 com-
pares estimates of the value of avoiding
each iliness using our quality-adjusted life-
year method with those using more tradi-
tional willingness-to-pay methods.12-18
This table illustrates that estimated values
using our quality-adjusted life-year method
are reasonably close to the ranges esti-
mated from illness-specific studies.
Table 2 also shows that different
illness-specific studies obtained highly
variable estimates for the same illness.
Moreover, although chronic arthritis and
chronic bronchitis are relatively similar in
their impact on functional status, using dif-
ferent approaches to contingent valuation
results in very different willingness-to-pay
estimates.12,13
Diswussion
This paper has highlighted the pri-
mary barrier to routinely estimating the
value ofavoided morbidityfrom health and
safety policies-adverse health effects as-
sociated with illnesses vary widely in type
and duration. Estimating the value of
avoiding death does not pose this problem
because of the unique qualities of death.
We have demonstrated a morbidity
valuation method that does not require
primary data or sophisticated estimation
procedures. Willingness-to-pay esti-
mates from our quality-adjusted life-year
method generally fall within the range of
those obtained using more rigorous meth-
ods. The main advantages of our method
are its relative simplicity, low cost, and
ability to be uniformly applied to many
different types of illnesses. Decision
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makers can use this method to generate
willingness-to-pay estimates for the value
of avoiding nonfatal illnesses, which can
be used to estimate the dollar benefit of
health and safety regulations. [J
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